Animal-brain-derived peptide/amino-acid mixture; neurological medicinal product in some countries

Cerebrolysin

aka Porcine brain protein hydrolysate peptide fraction

Evidence grade

Moderate human evidence

for cognitive and functional recovery in dementia, stroke rehabilitation and traumatic brain injury (the nationally authorised uses); healthy-person nootropic use is untested

User score everyone · n = 13

US FDA Not approved checked 2026-11-13

WADA 2026 Not named no clearance either · checked 2026-11-13

EU Austrian national authorization 1-21380 documented; central EMA authorization not found. · checked 2026-11-13

B dementia, stroke rehabilitation, brain injury (nationally authorised)
D nootropic in healthy people

Goals: Recovery & injury · Cognition & mood Compare with another peptide →

User reports

approximate — combined from two independent Reddit reads

Men 45–60

0 men aged 45–60

No reports in this group yet.

All men

0 men

No reports in this group yet.

Everyone

13 people

Positive: 4 of 13 (31%)
Mixed: 3 of 13 (23%)
Negative: 1 of 13 (8%)
No effect: 1 of 13 (8%)
Unclear: 4 of 13 (31%)

Benefits reported of 13

Side effects reported of 13

Why people stopped of 13

Stopped 1 of 13 (8%) Used with other compounds 3 of 13 (23%)

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.

In their words

“dramatically reduced anxiety and negative internal chatter, much better sleep, better emotional control”

positiver/Cerebrolysin
“My main negative side effect was frontal head pressure/tension and some mental heaviness later in the day”

side effectr/Cerebrolysin
“I was expecting some improvements in cognitive function, mood, or overall mental clarity, but I haven't felt any different.”

no effectr/Cerebrolysin
“I completed my first Cerebrolysin cycle using 5ml IM, 5 days on and 2 days off for 4 weeks, 20 injections total.”

positiver/Cerebrolysin
“During my last cycle I experienced significant cognitive benefits. Lowered anxiety. Reduced depression. Better mood. Much better sleep.”

positiver/Cerebrolysin
“Negatives reduced appetite, low mood, brain fog, anxiety, GI upset and reduced sleep time.”

negativer/Cerebrolysin

Read summaries and method notes

Read 1. No counted reporter explicitly stated male sex and an age of 45–60, so the priority cohort is empty. Three detailed users described cognitive, mood/anxiety or sleep improvements, but each also reported negatives such as head pressure, headaches, mental heaviness, muscle tension or a post-cycle crash; a fourth user completed 14 low-volume doses without noticing any effect. Several benefits emerged only after multiple weeks, including the reported stuttering improvement around weeks three to four. The no-effect case shows that response was not universal even within the self-selected Cerebrolysin community. Dose notation was inconsistent in Reddit posts, so verbatim strings are retained rather than normalized.

Read 2. No man aged 45–60 (one 49F). Thirteen users: 4 positive, 3 mixed, 1 negative, 1 no effect, 4 unclear — cognition (including a lifelong stutter 90% better after a 4-week IM cycle), mood/anxiety, energy, sleep. Side effects: low mood including a heavy post-cycle "dopamine crash", GI pain, brain fog, a vasovagal reaction; a 10 mL/day IV user reported anxiety, insomnia, brain fog and GI upset. Intranasal use of ampoules was warned against.

Note 1. No age-qualified male reports in this sample. Reports came primarily from a dedicated Cerebrolysin subreddit, creating strong community-selection bias.

Note 2. Zero stated male 45-60 posters. High-volume IM and IV protocols show much higher adverse-event rates than 2-5 mL IM cycles.

Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.

Summary

Porcine brain-derived neuropeptide mixture. Contains ~25% low-molecular-weight peptides + free amino acids from enzymatic breakdown of porcine brain proteins. MW: mixed (peptides <10 kDa).

Proposed mechanism

Cerebrolysin is a mixture rather than a single defined peptide. The following neurotrophin, PI3K/Akt, MAPK/ERK, neurogenesis, myelin and amyloid mechanisms are model-specific hypotheses, not verified formulation components or established human treatment effects.:

Neurotrophic factor mimicry — activates PI3K/Akt and MAPK/ERK pathways, promoting neuronal survival and synaptic plasticity
Neurogenesis — stimulates neural progenitor cell proliferation in hippocampus (preclinical hypothesis; the claimed human imaging support was not verified)
Anti-apoptotic — protects neurons from excitotoxicity and oxidative damage
Oligodendrogenesis — promotes myelin repair (relevant to white matter integrity in aging)
Amyloid modulation — reduces amyloid plaque burden in Alzheimer's animal models

Clinical context: RCTs exist in stroke, TBI, Alzheimer disease and vascular dementia, with mixed results. Austrian national authorization is documented; the “30+ countries” list and comparative endorsement were not verified. National authorization does not establish EU-wide approval or healthy-person benefit. Austrian label

Safety

Possible increased nonfatal serious adverse events in acute ischemic stroke
Life-threatening anaphylaxis documented
Contraindications include hypersensitivity, status epilepticus and severe renal impairment
Seizure, agitation/insomnia and rapid-administration reactions; antidepressant/MAOI interactions

From labels, regulators and trials. No signal in small studies ≠ safe.

Legal status

US FDANot approved

Not FDA-approved. FDA orphan record for porcine-brain peptide fraction says designation withdrawn/revoked and no orphan approval. Not on July 23–24, 2026 PCAC agenda or October HHS Appendix A; no new approval found. Source

checked 2026-11-13

WADA 2026Not named

Not named; IV method restriction M2.2 may apply. Source

checked 2026-11-13

EU

Austrian national authorization 1-21380 documented; central EMA authorization not found.

checked 2026-11-13

Re-check pending: HHS interim policy is a draft; re-check after the comment period.

Evidence B cognitive and functional recovery in dementia, stroke rehabilitation and traumatic brain injury (the nationally authorised uses); healthy-person nootropic use is untested

B stands, with a caveat. It is authorised by national regulators (Austria and others) for neurological indications that are the same kind of use it is marketed for, and adequately reported positive placebo-controlled RCTs exist behind that (Alzheimer 279 patients, vascular dementia 242, CARS 208, CAPTAIN II 142). That is what separates it from thymalin, DSIP, Semax and Selank. Against it: the largest stroke trial (CASTA, 1,070) was neutral and Cochrane 2023 finds no survival benefit and more non-fatal serious events in acute stroke. For a healthy person taking it as a nootropic there are no trials at all - that use alone would be D.

Human trials · 8

PMID 222828842012Double-blind placebo-controlled RCT (CASTA) 1,070 people

Acute ischemic stroke

Neutral confirmatory endpoint; severe-stroke subgroup findings were post hoc. Source
PMID 230091932013Double-blind placebo-controlled RCT (CERE-LYSE-1; online 2012) 119 people

Acute ischemic stroke receiving alteplase

Stopped after interim analysis for no 90-day mRS benefit; some early secondary outcomes favored treatment. Source
PMID 265641022016Double-blind placebo-controlled exploratory RCT (CARS) 208 people

Early stroke rehabilitation

Positive day-90 arm-function outcome; confirmatory larger trial requested by authors. Source
PMID 164203922006Double-blind placebo-controlled dose-ranging RCT 279 people

Mild-to-moderate Alzheimer disease

10 mL arm improved cognition and global impression at 24 weeks; higher doses did not significantly improve cognition. Source
PMID 206565162011Double-blind placebo-controlled RCT; online 2010 242 people

Vascular dementia

Reported improved combined cognitive/global clinical endpoint. Source
PMID 318979412020Double-blind placebo-controlled RCT (CAPTAIN II; 139 analyzed) 142 people

Moderate-to-severe traumatic brain injury

Positive day-90 multidimensional endpoint; small-to-medium reported effect. Source
PMID 399576122025Double-blind placebo-controlled exploratory RCT (ESCAS; 123 ITT) 132 people

Nonfluent aphasia after ischemic stroke; speech therapy in both arms

Greater language-score improvement at day 90; exploratory two-center study. Source
PMID 408511882025Open-label prospective comparative observational study (C-REGS2; target population 1769) 1,865 people

Moderate acute ischemic stroke

Reported superior functional outcomes; nonrandomized design limits causal inference.

Bar length = trial size on a log scale.

Dose ranges

Reported ranges from labels and studies, with context. Not a recommendation.

clinical trial
30 mL/day IV for 10 days (CASTA); 30 mL/day for 21 days with rehabilitation (CARS) Source
clinical trial
10–60 mL IV, 5 days/week for 4 weeks then twice/week for 8 weeks (Alzheimer dose-ranging study) Source
approved label
Austrian label: dementia 10–30 mL/day for 4 weeks; ischemic stroke 20–50 mL/day for 10–21 days; TBI 20–50 mL/day for 7–30 days; IM administration limited to 5 mL Source on a non-primary host — not linked

Editorial ratings EDITORIAL

Editors’ judgement, 0–5. Opinion, not data; separate from grade and user score.

Not rated yet.

Sources

Reddit threads read · 9

5 further sources on commercial or non-primary hosts not listed.

Research checked 2026-11-13.

Item	Reports
Focus / cognition	5 of 13 (38%)
Mood / anxiety	3 of 13 (23%)
Energy	2 of 13 (15%)
Other	2 of 13 (15%)
Libido	1 of 13 (8%)
Sleep	1 of 13 (8%)

Item	Reports
Other	4 of 13 (31%)
GI upset	2 of 13 (15%)
Headache	2 of 13 (15%)
Low mood	2 of 13 (15%)
Anxiety	1 of 13 (8%)
Fatigue	1 of 13 (8%)
Insomnia	1 of 13 (8%)